. Author manuscript; available in PMC: 2020 Jul 15.

Published in final edited form as: Antib Ther. 2020 Jun 6;3(2):146–154. doi: 10.1093/abt/tbaa012

Table 1.

Anti-CD20 bispecific antibodies have encouraging activities. ORR, objective response rate; CR, complete remission.

	Study	Indolent NHL		Aggressive B-NHL
	Study	ORR	CR	ORR	CR
bsAbs	Mosunetuzumab Group B	63% N = 67 (2.8 – 40 mg)	43%	38% N = 98 (2.8 – 40 mg)	20%
	Regeneron1979	93% N = 14	71%	57% N = 7 (80 −160 mg)	57%
	CD20-TCB ≥600 μg	53% N = 70	36%	100% N = 8	100%
CAR-T	JULIET (Tisagenlecleucel)	n/a	n/a	50% N = 68	32%
CAR-T	ZUMA-1 (Axicabtagene ciloleucel)	n/a	n/a	73% N =101	52%

Source: adapted from Dr. Budde’s presentation with her permission